[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1998052958A1 - Proteine 3 de decouplage d'origine humaine - Google Patents

Proteine 3 de decouplage d'origine humaine Download PDF

Info

Publication number
WO1998052958A1
WO1998052958A1 PCT/US1998/010215 US9810215W WO9852958A1 WO 1998052958 A1 WO1998052958 A1 WO 1998052958A1 US 9810215 W US9810215 W US 9810215W WO 9852958 A1 WO9852958 A1 WO 9852958A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
ucp3
host cell
expression vector
uncoupling protein
Prior art date
Application number
PCT/US1998/010215
Other languages
English (en)
Inventor
Qingyun Liu
Fang Chen
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9716886.8A external-priority patent/GB9716886D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to EP19980923517 priority Critical patent/EP1012155A4/fr
Priority to CA002289945A priority patent/CA2289945A1/fr
Priority to JP55052298A priority patent/JP2002502240A/ja
Publication of WO1998052958A1 publication Critical patent/WO1998052958A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • the present invention relates to an isolated nucleic acid molecule (polynucleotide) which encodes a novel human uncoupling protein, referred to throughout as uncoupling protein 3 (UCP3).
  • UCP3 uncoupling protein 3
  • the present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding human UCP3, substantially purfied forms of associated human UCP3, human UCP3 mutant proteins, and methods associated with identifying compounds which modulate energy expenditure and body weight regulation, as well as affecting diseases such as obesity and diabetes. BACKGROUND OF THE INVENTION
  • human UCP2 discloses a gene encoding both a mouse and human mitochondrial uncoupling protein, designated mouse UCP2 and human UCP2, respectively.
  • the deduced human amino acid sequence encodes a 33 kD protein which is approximately 95% homologous to the mouse protein at the amino acid level.
  • human UCP2 comprises 3 mitochondrial carrier protein motifs and an ATP binding site.
  • the authors show a wide range of tissue specific expression of the human ucp2 gene, including skeletal muscle, lung, heart, placenta, stomach, as well as immune systems tissue such as spleen, thymus, leukocytes, macrophages and bone marrow.
  • the authors mapped the human ucp2 gene to chromosome 11, which has been linked to obesity and hyperinsulinaemia in the mouse.
  • a nucleic acid molecule expressing an additional human uncoupling protein in such a specific manner would be extremely useful in screening for compounds acting as a modulator of to obesity and hyperinsulinaemia. Such a compound or compounds will be useful in controlling obesity as well as deleterious indications associated with obesity, such as diabetes. Additionally, such a nucleic acid molecule will be useful in gene therapy applications to overcome the deleterious effects of obesity and obesity-related complications, such as diabetes. The present invention addresses and meets this need.
  • the present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel vertebrate uncoupling protein.
  • the present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel human uncoupling protein.
  • the present invention also relates to a purified or isolated nucleic acid molecule which encodes a human uncoupling protein which is predominantly expressed within human skeletal muscle.
  • FIG. 1A-1B A preferred aspect of the present invention is disclosed in Figure 1A-1B and SEQ ID NO: 11, a purified human cDNA encoding a novel uncoupling protein, UCP3.
  • Another specific embodiment of the present invention relates to isolated biologically active fragments or mutants of a nucleic acid molecule encoding human uncoupling protein 3, disclosed herein in Figure 2A-2F, Figure 3 and SEQ ID NO: 12.
  • Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.
  • the present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel mouse uncoupling protein, as set forth as SEQ ID NO:17.
  • the present invention also relates to a purified or isolated nucleic acid molecule which encodes a mouse uncoupling protein which is predominantly expressed within human skeletal muscle, the expressed protein as set forth in SEQ ID NO:18.
  • the purified nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
  • the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
  • RNA ribonucleic acid molecule
  • the present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified mammalian nucleic acid molecules disclosed throughout this specification.
  • the present invention also relates to subcellular membrane fractions of the recombinant host cells (both prokaryotic and eukaryotic as well as both stably and transiently transformed cells) comprising the nucleic acids of the present invention. These subcellular membrane fractions will comprise UCP3 at levels substantially above wild type levels and hence will be useful in various assays described throughout this specification.
  • the present invention also relates to a substantially purified human uncoupling protein wherein the native form is substantially localized within mitochondria of skeletal muscle.
  • FIG. 2 A preferred aspect of the present invention is disclosed in Figure 2 and SEQ ID NO: 12, the amino acid sequence of the exemplified human uncoupling protein, hUCP3.
  • FIG. 7 Another preferred aspect of the present invention is disclosed in Figure 7 and SEQ ID NO:18, the amino acid sequence of the exemplified mouse uncoupling protein, mUCP3.
  • the present invention also relates to biologically active fragments and/or mutants of a novel human uncoupling protein, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.
  • the present invention also relates to methods of expressing the
  • UCP proteins or protein fragments disclosed herein assays employing these human UCPs, cells expressing these UCPs, and compounds identified through the use of these UCPs, including modulators of energy expenditure and body weight regulation, either through direct contact with the mitochondrial uncoupling protein, or a compound which acts in trans to modulate UCP expression.
  • modulators identified in this process are useful as therapeutic agents for controlling obesity, diabetes and other related diseases.
  • Figure 1A and Figure IB show the nucleotide sequence (SEQ ID NO: 11) which comprises the full-length cDNA encoding human uncoupling protein 3.
  • Figure 2A - Figure 2F show the translation of the open reading frame (SEQ ID NO: 12) of the full-length human uncoupling protein 3 nucleotide sequence.
  • Figure 3 shows the amino acid sequence of human uncoupling protein 3 (SEQ ID NO:12).
  • Figure 4A, Figure 4B and Figure 4C show Northern blot analysis of human uncoupling protein 3 in human tissue.
  • Figure 5 shows the orientation of vector and gene specific primers used to screen a human fetal brain cDNA library for a full-length human UCP3 cDNA.
  • Figure 6A and 6B shows the nucleotide sequence (SEQ ID NO: 17) of a cDNA which encodes the full-length mouse uncoupling protein 3.
  • Figure 7 shows the amino acid sequence (SEQ ID NO: 18) of the mouse uncoupling protein 3.
  • Figure 8A, Figure 8B and Figure 8C show flow cytometry analysis of mitochondria membrane potential with UCP3 expression in yeast.
  • TheS. cerevisiae strain W303 containing vector alone ( Figure 8A) or UCP3 expression plasmids ( Figure 8B and Figure 8C) were stained with the potential sensitive dye, DiOC6 and analyzed by FACS.
  • the X-axis represents the intensity of fluorescence on logarithmic scale while the Y-axis indicates the number of cells.
  • “+gal” indicates that cells were induced with galactose for 5 hours
  • "-gal” indicates cells were maintained in raffinose media without the induction by galactose.
  • a decrease in fluorescence intensity indicates a reduction in
  • Figure 9A and Figure 9B shows the response of UCP3 expression to adenovirus-mediated leptin treatment.
  • Figure 9A shows measurement of weight loss.
  • Y-axis indicates the average weight expressed in percentage of weight releative to the day of injection (Day 0).
  • Figure 9B shows UCP3 mRNA level.
  • Y-axis indicates the relative level of UCP3 mRNA (the average of the Adb-gal and control animals is assigned a value of 1). Standard deviation for each group is as marked.
  • Ad-Leptin first generation El-deleted, replication deficient adenoviral vector expressing leptin
  • HD-leptin helper-dependent adenoviral vector expressing leptin
  • Adb-gal first generation adenoviral vector expressing b-galactosidase
  • Control untreated.
  • the present invention relates to isolated nucleic acid and protein forms which represent a vertebrate uncoupling protein, preferably human and mouse forms.
  • the isolated genes and concomitant translation products which make up a portion of the present invention may be used in various ways in the treatment of obesity and other related diseases, including but not limited to diabetes.
  • the uncoupling protein of the present invention is a protein which is translated in the cytosol from a nuclear encoded mRNA transcript. This uncoupling protein is presumably imported into the mitochondrial inner membrane post-translationally. The process of oxidative phosphorylation pumps protons to the outside of the inner membrane of the mitochondria, leading to the generation of a membrane potential across the inner membrane.
  • the purified uncoupling proteins of the present invention have the ability to uncouple the protonmotive force associated with oxidative phosphorylation, resulting in the concomitant release of large amounts of energy. It will be within the scope of the present invention to use the herein disclosed nucleic acids to construct recombinant vectors and recombinant host cells wherein the human UCP3 gene is expressed, either stably or transiently. Such transformed recombinant cell lines will be useful in screening for modulators of UCP3 activity, and hence, as effectors of energy expenditure and body weight regulation.
  • the isolated nucleic acid fragments of the present invention will also be useful in gene therapy applications regarding therapeutic treatment of obesity and obesity related indications, including but not limited to diabetes, as well as conditions such as mitochondrial-associated hypermetabolism.
  • the present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel human uncoupling protein.
  • the present invention also relates to a purified or isolated nucleic acid molecule which encodes a human uncoupling protein which is predominantly expressed within human skeletal muscle.
  • FIG. 1 A preferred aspect of the present invention is disclosed in Figure 1 and SEQ ID NO:11, a purified human cDNA encoding a novel uncoupling protein, UCP3, which is as follows: TCGAACTCAC TCACCTCCCC TCTCACCTCA CTGCCCTCAC CAGCCAGCCT CTTGTCAAGT GATCAGGCTG TCAACCAACT TCTCTAGGAT AAGGTTTCAG GTCAGCCTGT GTGTATAAGA CCAGTGCCAA GCCAGAAGCA GCAGAGACAA CAGTGAATGA CAAGGAGGGG CCATCCAATC CCTGCTGCCA CCTCCTGGGA TGGAGCCCTA GGGAGCCCCT GTGCTGCCCC TGCCGTGGCA GGACTCACAG CCCCACCGCT GCACTGAAGC CCAGGGCTGT GGAGCAGCTC TCCTTGGA CTCCTCTCGG CCCTAAAGGGACTGGCTGT GGAGCAGCTC TCCTTGGA CTCCTCTCGG CCCTAAAG
  • Another specific embodiment of the present invention relates to isolated biologically active fragments or mutants of a nucleic acid molecule encoding human uncoupling protein 3, disclosed herein as SEQ ID NO: 11 (see also Figure 1A-1B).
  • Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.
  • the purified nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
  • the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
  • RNA ribonucleic acid molecule
  • the present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.
  • the present invention also relates to a substantially purified human uncoupling protein wherein the native form is substantially localized within mitochondria of skeletal muscle.
  • FIG. 2A-2F A preferred aspect of the present invention is disclosed in Figure 2A-2F, Figure 3 and SEQ ID NO: 12, the amino acid sequence of the exemplified human uncoupling protein, UCP3, which is as follows:
  • the present invention also relates to biologically active fragments and/or mutants of a novel human uncoupling protein, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.
  • the present invention also relates to methods of expressing the vertebrate UCP proteins or protein fragments disclosed herein, assays employing these human and mouse UCPs, cells expressing these UCPs, and compounds identified through the use of these UCPs, including modulators of energy expenditure and body weight regulation, either through direct contact with the mitochondrial uncoupling protein, or a compound which acts in trans to modulate ucp expression. Such modulators identified in this process are useful as therapeutic agents for controlling obesity, diabetes and other related diseases.
  • nucleic acid fragment and protein fragments of the present invention include, but are not limited to, identifiying trans- acting factors which regulate UCP3 expression. It will then be possible to identify compounds which affect a protein or protein complex acting in trans to up or down regulate vertebrate UCP3 expression such that administration of such a compound or pharmaceutically acceptable salt in a pharmaceutically acceptable formulation will modulate UCP3 expression and in turn the degree of energy expenditure within the patient.
  • the present invention also relates to methods of expressing a nucleic acid fragment encoding UCP, including but not limited to the exemplified human and/or mouse ucp3 or gene fragments disclosed herein, recombinant prokaryotic and eukaryotic expression vectors containing such a nucleic acid fragment, recombinant host cells transfected with these vectors wherein a ucp gene or gene fragment is expressed at predetermined levels through appropriate vector construction, and compounds identified through the interaction with either regulatory regions of a ucp gene or a compound which interacts with the mature, mitochondrial-localized form of a UCP protein.
  • Such a compound may be useful in treating disorders associated with regulation of body weight and concomitant intake and expeniture of energy (or lack thereof), including but not limited to obesity and diabetes.
  • the present invention also relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel mouse uncoupling protein, as set forth as SEQ ID NO:17, and as follows: CCAGGAACAG CAGAGACAAC AGTGAATGGT GAGGCCCGGC CGTCAGATCC TGCTGCTACC TAATGGAGTG GATCCTTAGG GTGGCCCTGC ACTACCCAAC CTTGGCTAGA CGCACAGCTT CCTCCCTGAA CTGAAGCAAA AGATTGCCAG GCAAGCTCTC TCCTCGGACC TCCATAGGCA GCAAAGGAAC CAGGCCCATT CCCCGGGACC ATGGTTGGAC TTCAGCCCTC CGAAGTGCCT CCCACAACGG TTGTGAAGTT CCTGGGGGCC GGCACTGCGG CCTGTTTTGC GGACCTCCTC ACTTTTCCCC TGGACACCGC CAAGGTCCGT CTGCAGATCC AAGGGGAAGGCT
  • the present invention also relates to mouse forms of isolated biologically active fragments or mutants of a nucleic acid molecule encoding human uncoupling protein 3, disclosed herein as SEQ ID NO: 17 (see also Figure 6A-6B).
  • Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy- terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.
  • the purified mouse nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
  • DNA deoxyribonucleic acid molecule
  • cDNA complementary DNA
  • synthetic DNA such as a synthesized, single stranded polynucleotide.
  • the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
  • the present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified mouse nucleic acid molecules disclosed throughout this specification.
  • the present invention also relates to a substantially purified mouse uncoupling protein wherein the native form is substantially localized within mitochondria of skeletal muscle.
  • a preferred aspect of the present invention is disclosed in Figure 7 and SEQ ID NO: 18, the amino acid sequence of the exemplified mouse uncoupling protein, UCP3, which is as follows: MVGLQPSEVP PTTWKFLGA GTAACFADLL TFPLDTAKVR LQIQGENPGA QSVQYRGVLG TILTMVRTEG PRSPYSGLVA GLHRQMSFAS IRIGLYDSVK QFYTPKGADH SSVAIRILAG CTTGAMAVTC AQPTD ⁇ A/KVR FQAMIRLGTG GERKYRGTMD AYRTIAREEG VRGLWKGT P NITRNAIVNC AEMVTYDIIK EKLLESHLFT DNFPCHFVSA FGAGFCATW ASPVDWKTR YMNAPLGRYR SPLHCMLKMV AQEGPTAFYK GFVPSFLR
  • the present invention also relates to biologically active fragments and/or mutants of a novel mouse uncoupling protein, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy- terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.
  • this invention is also directed to those DNA sequences which contain alternative codons which code for the eventual translation of the identical amino acid.
  • a sequence bearing one or more replaced codons will be defined as a degenerate variation.
  • mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.
  • DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally-occurring peptide.
  • Methods of altering the DNA sequences include, but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.
  • nucleic acid, protein, or respective fragment thereof in question has been substantially removed from its in vivo environment so that it may be manipulated by the skilled artisan, such as but not limited to nucleotide sequencing, restriction digestion, site-directed mutagenesis, and subcloning into expression vectors for a nucleic acid fragment as well as obtaining the protein or protein fragment in pure quantities so as to afford the opportunity to generate polyclonal antibodies, monoclononal antibodies, amino acid sequencing, and peptide digestion. Therefore, the nucleic acids claimed herein may be present in whole cells or in cell lysates or in a partially purified or substantially purified form.
  • a nucleic acid is considered substantially purified when it is purified away from environmental contaminants.
  • a nucleic acid sequence isolated from cells is considered to be substantially purified when purified from cellular components by standard methods while a chemically synthesized nucleic acid sequence is considered to be substantially purified when purified from its chemical precursors.
  • UCP3 may refer to any vertebrate form of UCP3, including but not limited to mouse or human UCP3.
  • BAT brown adipose tissue.
  • EST expressed sequence tag.
  • a "biologically active equivalent” or “functional derivative” of a wild type UCP3 possesses a biological activity that is substantially similar to the biological activity of the wild type UCP3.
  • the term “functional derivative” is intended to include the “fragments,” “mutants,” “variants,” “degenerate variants,” “analogs” and “homologues” or to “chemical derivatives” of the wild type UCP3 protein.
  • fragment is meant to refer to any polypeptide subset of wild type UCP3.
  • mutant is meant to refer to a molecule that may be substantially similar to the wild type form but possesses distinguishing biological characteristics.
  • Such altered characteristics include but are in no way limited to altered substrate binding, altered substrate affinity and altered sensitivity to chemical compounds affecting biological activity of the UCP3 or UCP3 functional derivative.
  • variant is meant to refer to a molecule substantially similar in structure and function to either the entire wild type protein or to a fragment thereof.
  • a molecule is "substantially similar” to a wild type UCP3-like protein if both molecules have substantially similar structures or if both molecules possess similar biological activity. Therefore, if the two molecules possess substantially similar activity, they are considered to be variants even if the structure of one of the molecules is not found in the other or even if the two amino acid sequences are not identical.
  • analog refers to a molecule substantially similar in function to either the entire wild type UCP3-like protein or to a fragment thereof.
  • Any of a variety of procedures may be used to clone UCP3. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, Proc. Natl. Acad. Set.85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of UCP3 cDNA.
  • These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the UCP3 cDNA following the construction of an UCP3-containing cDNA library in an appropriate expression vector system; (3) screening a UCP3- containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the UCP3 protein; (4) screening a UCP3-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the UCP3 protein.
  • EST expressed sequence tag
  • This partial cDNA is obtained by the specific PCR amplification of UCP3 DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other UCP3 kinases which are related to the UCP3 protein; (5) screening an UCP3-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the UCP3 protein.
  • This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of UCP3 cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NOS 1 or 2 as a template so that either the full length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full length version of the nucleotide sequence encoding UCP3.
  • libraries as well as libraries constructed from other cells types or species types, may be useful for isolating a UCP3- encoding DNA or a UCP3 homologue.
  • Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than human cells or tissue such as murine cells, rodent cells or any other such vertebrate host which may contain a UCP3-encoding DNA.
  • UCP3 gene may be isolated by oligonucleotide- or polynucleotide- based hybridization screening of a vertebrate genomic library, including but not limited to a human genomic library, a murine genomic library and a rodent genomic library, as well as concomitant human genomic DNA libraries.
  • suitable cDNA libraries may be prepared from cells or cell lines which have UCP3 activity.
  • the selection of cells or cell lines for use in preparing a cDNA library to isolate a UCP3 cDNA may be done by first measuring cell associated UCP3 activity using any known assay for UCP3 activity.
  • cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook, et al., 1989, Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagent.
  • DNA encoding UCP3 may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Sambrook, et al., supra.
  • the amino acid sequence or DNA sequence of UCP3 or a homologous protein may be necessary.
  • the UCP3 or a homologous protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be determined for the PCR amplification of a partial UCP3 DNA fragment. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized.
  • the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the UCP3 sequence but others in the set will be capable of hybridizing to UCP3 DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still sufficiently hybridize to the UCP3 DNA to permit identification and isolation of UCP3 encoding DNA. Alternatively, the nucleotide sequence of a region of an expressed sequence may be identified by searching one or more available genomic databases.
  • Gene-specific primers may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs.
  • the appropriate nucleotide sequence for use in a PCR-based method may be obtained from SEQ ID NOS: 1 or 2, either for the purpose of isolating overlapping 5' and 3' RACE products for generation of a full-length sequence coding for UCP3, or to isolate a portion of the nucleotide sequence coding for UCP3 for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence encoding UCP3 or UCP3-like proteins.
  • the human UCP3 full length cDNA of the present invention was generated by a novel method of cDNA screening.
  • the extension of partial cDNA sequences have historically been achieved with one or both of the two commonly used methods: filter screening of cDNA libraries by hybridization with labeled probes, and 5'- and 3'-RACE with total cellular mRNA by PCR.
  • the first method is effective but laborious and slow while the latter method is fast but limited in efficiency.
  • This RACE protocol is hindered by limited length of extension due to the use of the entire cellular mRNA population in a single reaction. Since smaller fragments are amplified much more efficiently than larger fragments by PCR in the same reaction, PCR products obtained using the second method are often quite small.
  • This portion of the present invention marks an improvement upon known methods of cDNA library screening by initially constructing and subdividing cDNA libraries followed by isolating 5'- and 3'- flanking fragments by PCR. Since each pool is unlikely to contain more than one clone for a given gene which is low to moderately expressed, competition between large and small PCR products in one pool does not exist, making it possible to isolate fragments of various sizes.
  • One defininte advantage of the method disclosed in this specification is the efficiency, throughput, and its potential to isolate alternatively spliced cDNA forms.
  • this portion of the invention relates to a process for rapid extension of a partial cDNA sequence based on subdividing a primary cDNA library and DNA amplification by polymerase chain reaction (PCR).
  • a cDNA library is constructed with cDNA primed by random, oligo-dT or a combination of both random and oligo-dT primers and then subdivided into pools at approximately 10,000 -20,000 clones per pool. Each pool is amplified separately and therefore represents an independent portion of the cDNA molecules from the original mRNA source. Samples from all the pools are collected and transferred into 96- well plates.
  • a partial cDNA sequence such as SEQ ID NO:l or 2
  • positive pools containing the partial cDNA sequence are first identified by PCR with a pair of primers complementary to the cDNA sequence.
  • Each positive pool in the library contains an independent clone of the cDNA sequence; within each clone are embedded the partial cDNA sequence and its flanking fragments.
  • the flanking fragments are isolated by PCR with primers complementary to the known vector and cDNA sequences and then sequenced directly.
  • the DNA sequences from these fragments plus the original partial cDNA sequence are assembled into a continuous fragment, resulting in the extension of the partial cDNA sequence and the eventual determination of its full-length gene sequence by repeating the process, if necessary, until a complete open reading frame is obtained.
  • the fundamental principle of this process is to subdivide a complex library into pools of about 10,000 to about 20,000 clones.
  • a library of two million primary clones, a number large enough to cover most mRNA transcripts expressed in the tissue, can be subdivided into 188 pools and stored in two 96-well plates. Since the number of transcripts for most genes is fewer than one copy per -10,000 transcripts in total cellular mRNA, each pool is unlikely to contain more than one clone for a given cDNA sequence. Such reduced complexity makes it possible to use PCR to isolate flanking fragments of partial cDNA sequences larger than those obtained by known methods.
  • the foregoing process is exemplifed for isolation and characterization of a full-length cDNA encoding human UCP3.
  • a random and oligo dT primed fetal brain cDNA library consisting of approximately 4 million primary clones was constructed in the plasmid vector pBluescript (Stratagene, LaJolla, CA). The primary clones were subdivided into 188 pools with each pool containing -20,000 clones. Each pool was amplified separately and the resulting plasmid pools were collected and transferred into two 96-well plates.
  • Primer pairs from the 5' and 3' portion of SEQ ID NO:l (EST-AA192136), 5' and 3' oligonucleotides from SEQ ID NO:4 (EST-AA192553) as well as oligonucleotide primers both 5' and 3' of the polylinker sequence of the vector (in this case, pBluescript SK " ) were used to scan this human fetal brain cDNA library distributed in a 96-well plate separately. Initial positive pools were identifed with the 5' and 3' primers from AA192136 (SEQ ID NOS: 5 and 6) and the pBluescript primers (SEQ ID NOS:9 and 10).
  • the positive pools were scanned again by PCR with both pBluescript primers as well as the 5' and 3' primers associated with the 3' EST, AA192553 (primers 3U3F and 3U3R).
  • This step showed that scanning with 838F (pBSK ⁇ , SEQ ID NO: 9) and 3U3F (hybridizing to the 3' EST AA192553; SEQ ID NO:8), generated a 2.4 Kb cDNA fragment.
  • This cDNA fragment was subcloned into the vector pTA2.1 (Invitrogen, San Diego, CA, USA) by TA cloning. Four positive clones, the original PCR fragment, as well the I.M.A.G.E.
  • clone #628529 (SEQ ID NOS:l and 2) were sequenced by primer walking. The sequences were then assembled into a contig of 2340 base pairs which is as set forth in SEQ ID NO: 11 and Figure 1A and Figure IB. This sequence contains an open reading frame that encodes a polypeptide of 312 amino acids as set forth in SEQ ID NO:12 and Figures 2A-2F and Figure 3.
  • the cDNA as set forth in SEQ ID NO: 11 was identified as a full- length cDNA fragment from a single positive pool.
  • Figure 5 shows the vector and EST (gene) specific primers used to isolate the human UCP3 gene. In this instance, the entire coding region and 3' untranslated region was retrieved by the 838F and 3U3F primer combinantion.
  • multiple primer combinations from an EST or other partial cDNA sequence, in combination with flanking vector primer oligonucleotides may be used to "walk" in both directions away from the internal gene specific sequence and respective primers such that a contig representing a full length cDNA may be constructed.
  • This procedure relies on the ability to screen multiple pools which comprise a representive portion of the total cDNA library. This procedure is not dependent upon using a cDNA library with directionally cloned inserts. Instead, both 5' and 3' vector and gene specific primers are added and a contig map is constructed from additional screening of positive pools using both vector primers and gene specific primers.
  • gene specific primers are intially constructed from a known nucleic acid fragment such as an expressed sequence tag.
  • gene specific primers are utilized from the 5' and 3' boundaries of the newly identified regions of the cDNA. As the walk continues,
  • SUBSTTTUTE SHEET (RULE 26) continues, there is still no requirement that the vector orientation of a yet unidentified fragment be known. Instead, all combinations are tested on a positive pool and the actual vector orientation is determined by the ability of certain vector/gene specific primers to generate the predicted PCR fragment. A full-length cDNA may then be easily constructed by known subcloning procedures.
  • a variety of mammalian expression vectors may be used to express recombinant UCP3 in mammalian cells.
  • Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host.
  • Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells.
  • An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters.
  • a promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis.
  • a strong promoter is one which causes mRNAs to be initiated at high frequency.
  • Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.
  • mammalian expression vectors which may be suitable for recombinant UCP3 expression, include but are not limited to, pcDNA3.1 (Invitrogen), pBlueBacHis2 (Invitrogen), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Bioloabs), pcDNAI, pcDNAIamp (Invitrogen), pcDNA3 (Invitrogen), pMClneo (Stratagene), pXTl (Stratagene), pSG5 (Stratagene), EBO- pSV2-neo (ATCC 37593) pBPV- 1(8-2) (ATCC 37110), pdBPV-MMTneo(342- 12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (
  • a variety of bacterial expression vectors may be used to express recombinant UCP3 in bacterial cells.
  • Commercially available bacterial expression vectors which may be suitable for recombinant UCP3 expression include, but are not limited to pCR2.1 (Invitrogen), pETlla (Novagen), lambda gtll (Invitrogen), pcDNAII (Invitrogen), pKK223-3 (Pharmacia).
  • a variety of fungal cell expression vectors may be used to express recombinant UCP3 in fungal cells.
  • Commercially available fungal cell expression vectors which may be suitable for recombinant UCP3 expression include but are not limited to pYES2 (Invitrogen), Pichia expression vector (Invitrogen).
  • insect cell expression vectors may be used to express recombinant receptor in insect cells.
  • Commercially available insect cell expression vectors which may be suitable for recombinant expression of UCP3 include but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen).
  • An expression vector containing DNA encoding a UCP3- like protein may be used for expression of UCP3 in a recombinant host cell.
  • Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as E.
  • L cells L-M(TK-) ATCC CCL 1.3
  • L cells L-M ATCC CCL 1.2
  • Saos-2 ATCC HTB-85
  • 293 ATCC CRL 1573
  • Raji ATCC CCL 86
  • CV-1 ATCC CCL 70
  • COS-1 ATCC CRL 1650
  • COS-7 ATCC CRL 1651
  • CHO-K1 ATCC CCL 61
  • 3T3 ATCC CCL 92
  • NIH/3T3 ATCC CRL 1658
  • HeLa ATCC CCL 2
  • C127I ATCC CRL 1616
  • BS-C-1 ATCC CCL 26
  • MRC-5 ATCC
  • the expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation.
  • the expression vector-containing cells are individually analyzed to determine whether they produce UCP3 protein. Identification of UCP3 expressing cells may be done by several means, including but not limited to immunological reactivity with anti-UCP3 antibodies, and the presence of host cell-associated UCP3 activity.
  • the cloned UCP3 cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector (such as pcDNA3.1, pCR2.1, pBlueBacHis2 and pLITMUS28) containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant UCP3.
  • an expression vector such as pcDNA3.1, pCR2.1, pBlueBacHis2 and pLITMUS28
  • Techniques for such manipulations can be found described in Sambrook, et al., supra , are discussed at length in the Example section and are well known and easily available to the artisan of ordinary skill in the art.
  • UCP3 DNA may also be performed using in vitro produced synthetic mRNA.
  • Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.
  • UCP3 cDNA molecules including but not limited to the following can be constructed: the full-length open reading frame of the UCP3 cDNA and various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and or 3' untranslated region of UCP3. UCP3 activity and levels of protein expression can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the UCP3 cDNA cassette yielding optimal expression in transient assays, this UCP3 cDNA construct is transferred to a variety of expression vectors
  • viruses including recombinant viruses, including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells.
  • UCP3 protein in host cells is quantified by a variety of techniques including, but not limited to, immunoaffinity and/or ligand affinity techniques.
  • UCP3-specific affinity beads or UCP3-specific antibodies are used to isolate 35 S-methionine labeled or unlabelled UCP3 protein.
  • Labeled UCP3 protein is analyzed by SDS-PAGE.
  • Unlabelled UCP3 protein is detected by Western blotting, ELISA or RIA assays employing UCP3 specific antibodies.
  • UCP3 protein may be recovered to provide UCP3 in active form.
  • UCP3 purification procedures are available and suitable for use.
  • Recombinant UCP3 may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography.
  • recombinant UCP3 can be separated from other cellular proteins by use of an immuno-affinity column made with monoclonal or polyclonal antibodies specific for full length UCP3, or polypeptide fragments of UCP3.
  • polyclonal or monoclonal antibodies may be raised against a synthetic peptide (usually from about 9 to about 25 amino acids in length) from a portion of the protein as disclosed in SEQ ID NO: 12.
  • Monospecific antibodies to UCP3 are purified from mammalian antisera containing antibodies reactive against UCP3 or are prepared as monoclonal antibodies reactive with UCP3 using the technique of Kohler and Milstein (1975, Nature 256: 495- 497).
  • Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for UCP3.
  • Homogenous binding refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the UCP3, as described above.
  • UCP3 specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of UCP3 or UCP3 synthetic peptide either with or without an immune adjuvant.
  • Preimmune serum is collected prior to the first immunization.
  • Each animal receives between about 0.1 mg and about 1000 mg of UCP3 associated with an acceptable immune adjuvant.
  • acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA.
  • the initial immunization consists of the UCP3 protein or UCP3 synthetic peptide in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both.
  • SC subcutaneously
  • IP intraperitoneally
  • Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization.
  • Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20°C.
  • Monoclonal antibodies (mAb) reactive with UCP3 are prepared by immunizing inbred mice, preferably Balb/c, with UCP3.
  • the mice are immunized by the IP or SC route with about 1 mg to about 100 mg, preferably about 10 mg, of UCP3 in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred.
  • the mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 mg of UCP3 in a buffer solution such as phosphate buffered saline by the intravenous (TV) route.
  • a buffer solution such as phosphate buffered saline
  • Lymphocytes from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art.
  • Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NSl/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred.
  • the antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%.
  • Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected form growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using UCP3 as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb.
  • SPIRA solid phase immunoradioassay
  • Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press.
  • Monoclonal antibodies are produced in vivo by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 10" to about 6 x 10" hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.
  • In vitro production of anti-UCP3 mAb is carried out by growing the hydridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb.
  • the mAb are purified by techniques known in the art.
  • Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of UCP3 in body fluids or tissue and cell extracts.
  • serological or immunological assays include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of UCP3 in body fluids or tissue and cell extracts.
  • UCP3 antibody affinity columns are made by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine
  • HC1 (pH 8).
  • the column is washed with water followed by 0.23 M glycine HC1 (pH 2.6) to remove any non-conjugated antibody or extraneous protein.
  • the column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing UCP3 or UCP3 fragments are slowly passed through the column.
  • the column is then washed with phosphate buffered saline until the optical density (A280) falls to background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6).
  • the purified UCP3 protein is then dialyzed against phosphate buffered saline.
  • the novel UCP3 of the present invention is suitable for use in an assay procedure for the identification of compounds which modulate UCP3 activity.
  • Modulating UCP3 activity includes the inhibition or activation of the protein and also includes directly or indirectly affecting the cell cycle regulatory properties associated with UCP3 activity.
  • Compounds which modulate UCP3 activity include agonists, antagonists, inhibitors, activators, and compounds which directly or indirectly affect regulation of the UCP3 activity and/or the UCP3 uncoupling activity.
  • the UCP3 of the present invention may be obtained from both native and recombinant sources for use in an assay procedure to identify UCP3 modulators.
  • an assay procedure to identify UCP3 modulators will contain the UCP3-protein of the present invention, and a test compound or sample which contains a putative
  • the test compounds or samples may be tested directly on, for example, purified UCP3 protein whether native or recombinant, subcellular fractions of UCP3-producing cells whether native or recombinant, and/or whole cells expressing the UCP3 whether native or recombinant.
  • the test compound or sample may be added to the UCP3 in the presence or absence of a known UCP3 modulator.
  • the modulating activity of the test compound or sample may be determined by, for example, analyzing the ability of the test compound or sample to bind to UCP3 protein, activate the protein, inhibit UCP3 activity, inhibit or enhance the binding of other compounds to the UCP3 protein, modifying receptor regulation, or modifying an intracellular activity.
  • the present invention also relates to subcellular membrane fractions of the recombinant host cells (both prokayotic and eukaryotic as well as both stably and transiently transformed cells) comprising the nucleic acids of the present invention.
  • These subcellular membrane fractions will comprise UCP3 at levels substantially above wild type levels and hence will be useful in various assays described throuhgout this specification.
  • the identification of modulators of UCP3 activity will be useful in treating disease states involving, as an example but not a limitation, obesity and diabetes, by manipulating the interrelated process of balancing food intake, energy expenditure and glucose metabolism within the patient. Therefore, modulators to treat hyperactive conditions of energy expenditure which originate in the mitochondria of skeletal muscle will also be within the purview of the present invention.
  • the present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding a UCP3 protein of the present invention or which modulates the function of a such a UCP3 protein.
  • Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non- proteinaceous organic molecules.
  • Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding the UCP3 protein, or the function of a UCP3 protein.
  • Compounds that modulate the expression of DNA or RNA encoding the UCP3 protein or the biological function thereof may be detected by a variety of assays.
  • the assay may be a simple "yes/no" assay to determine whether there is a change in expression or function.
  • the DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of UCP3 DNA, RNA or protein.
  • the recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of UCP3.
  • a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container.
  • the carrier would further comprise reagents such as recombinant UCP3 protein or anti-UCP3 antibodies suitable for detecting UCP3.
  • the carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.
  • Pharmaceutically useful compositions comprising modulators of UCP3 may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, or modified UCP
  • compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders.
  • the effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
  • compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
  • chemical derivative describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.
  • the present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.
  • the compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration.
  • the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
  • they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the active agents can be administered concurrently, or they each can be administered at separately staggered times.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • the Blastn search identified an expressed sequence tag (EST) detected among the Merck- Washington University EST's with accession number AA192136, which is: GGTGACCTACGACATCCTCAAGGAGAAGCTGCTGGACTACCACCTGCTCACTGACAACT TCCCCTGCCACTTTGTCTCTGCCTTTGGAGCCGGCTTCTGTGCCACAGTGGTGGCATCC CCGGTGGACGTGGTGAAGACCCGGTATATGAACTCACCTCCAGGCCAGTACTTCAGCCC CCTCGACTGTATGATAAAGATGGTGGCCCAGGAGCGCCACCAGCCTTCTACAAGGGATT TACACCCTCCTTTTTGCGTTTGGGATCCTGGAACGTGGTGATGTTCGTAACCTATGAGC AGCTGAAACGGGCCCTGATGAAAGTCCAGATGTTACGGGAATCACCGTTTTGAACAAGA CAAGAAGGCCACTGGTAGCTAACGTGTCCGAAACCAGTTAAGAATGGAAG (SEQ ID NO:l). An "N" residue is added at base
  • SEQ ID NO:l is a component of Stratagene ® muscle cDNA library
  • cDNA Image Clone No. 628529 This Stratagene muscle cDNA library was generated by standard methods and cDNAs are cloned unidirectionally into EcoRI/XhoI digested pBS(SK ' ) plasmid. The mRNA for this library was isolated from the skeletal muscle of an adult human patient suffering from malignant hyperthermia.
  • This cDNA clone is publically available by Genbank Accession No. AA192136, Image Clone ID No. 628529, and Washington University Clone ID No. zq02d09.rl. This construct is available from Research Genetics, Inc., 2130 Memorial Parkway SW, Hunstville, AL 35801 (http://www. resgen.com).
  • SEQ ID NO:l was used as a query to search Genbank with Blastn.
  • a second EST, with accession number Z28895 (and assigned Genbank number HSBB6C051) was identified and is disclosed throughout this specification as SEQ ID NO:3, which is: CGAGCAGCTGAAACGGGCCCTGATGAAAGTCCAGATGTTACGGGNATCACCGTTTTGAA CAAGACAAGAAGGCCACTGGTAGCTAACGTNTCCGAAACCAGTTAAGANTGGAAGAAAA CGGTCCATCCACGNACACATGGACACAGACCCACACATNTT (SEQ ID NO: 3 ) .
  • SEQ ID NO:2 shows an open reading frame encoding a novel protein fragment showing homology to human UCPl and human UCP2.
  • SEQ ID NO:2 represents the 5' portion of the cDNA Image Clone No. 628529. The 3' sequence read of cDNA Image Clone No.
  • 628529 has the accession number aal92553, which is as follows: TTTTTTTTGTTCTTACTCCCACACCTAAGGTGGAANTTCTTTTATTGAGTCATAATAAT TTCCCGAGAATTCCGAGTCCTGCTACTTTAGGTTCTTGCCCAGGAATCCACCTCTTTTC CCCCAAGCCCAACAATCCTTTGAGGTACTCATGATTGAGCGCGTGGTGGGGGGGGGTGG GGAAGAGGCTGCATGGGGGTGGGGCTCCTGTGGCTTCACGTCATCCACTGTCACCTCTG GTCCCCAAGTCTCTGGATCCTTTGGTCTCACCTCTAGACAACCGGCGGGGTTCAAACCT TCTTCCCTGGCAACTCCTCTCTGTCCCGACAAAATCTCTCCCAAGGCATTGTCCTTGTA GTTAGATTTACACAGAGCTTTTGCTTATAAAGTGCGTTCATGCCCAGCTTCTCACTT GCATGTCATAGCACCCCTGGTGAGGTGGACAGGGAAGGGATGGCTCCATTTTGTA GGGGGT
  • the exemplified full length cDNA of the present invention was generated by a novel method of cDNA screening as described in the Detailed Description of the Invention.
  • Primer pairs 5'-AAGCTGCTGGACTACCACCTGCTC-3' F29; SEQ ID NO:5
  • 5'-TACTGGCCTGGAGGTGAGTTCA-3' R147: SEQ ID NO:6 as designed from AA192136;
  • 5'-CCAAGCCCAACAATCCTTTGA-3' (3U3F; SEQ ID NO:7) and 5'-CCAAAGGATCCAGAGACTTGG-3' (3U3R; SEQ ID NO:8) as designed from AA192553, and pBluescript SK vector primers 838F (5'-TTGTGTGGAATTGTGAGCGGATAAC-3'; SEQ ID NO:9) and 578R (5'-CCAGGGTTTTCCCAGTCACGAC-3'; SEQ ID NO:10) were used to scan by PCR a human fetal brain cDNA library distributed in a 96-well plate separately.
  • UCP3.-9F.RI20mer (5'CATAGAATTCCAGGACTATGGTTGGAC3', SEQ ID NO:13), and UCP3.1308R.XhoI20mer
  • SUBST ⁇ UTE SHEET (RULE 26) (5'CATTCTCGAGCTACCAGTGGCCTTCTTG3', SEQ ID NO: 14) were used to generate a PCR product of human UCP3 tagged with EcoRI and Xhol sites at the 5' and 3' ends, respectively, using pCR2.1-UCP3.1 as the template.
  • the PCR product was digested with EcoRI and Xhol and purified from an agarose gel. This fragment was ligated into a yeast expression vector pYES2 (Invitrogen, San Diego, CA) that was also digested with EcoRI and Xhol such that UCP3 is under the control of S. cerevisiae GAL1 promoter. Multiple recombinants isolated after transformation into E.
  • coli were picked and sequenced using three UCP3 internal primers in combinatition with two pYES2 vector primers (5'CCCGGATCGGACTACTAGCA, (SEQ ID NO:15); 5'GGGGGGAGGGCGTGAATGTAA; [SEQ ID NO: 16]).
  • the diploid Saccharomyces cerevisiae strain W303 (MATa I a, canl-100, ade2-10, his3-ll,-15, leu2-2,-112, trpl-Dl, ura3-l) was also used for the expression of UCP3.
  • Human UCP3 was expressed under the control of GAL1 promoter in pYES2 (Invitrogen, San Diego, CA). Constructs were made directly in yeast using a gap repair strategy. The entire open reading frame of human UCP3 was amplified using a pair of primers that incorporated a yeast translation start site
  • the W303 strain containing the vector alone or UCP3 expression plasmid was streaked onto Sc-Ura media with 3% glycerol and 2% galactose and incubated at 30°C for 48 hours.
  • cells were grown in Sc-Ura media supplemented with raffinose.
  • Galactose was added to induce the expression of UCP3 for five hours.
  • Fluorescent probe DiOC6 (3,3'- dihexyloxacarbocyanine iodine) was added after cell concentration was adjusted to two millions per ml. Data were coDected and analyzed as described (Bouillaud et al., 1994. EMBO J. 13: 1990-1997).
  • DiOC6 was measured using flow cytometry analysis. Induction of UCP3 expression by galactose significantly reduced the membrane potential of mitochondria compared with strains containing vector alone ( Figure 8A and 8C). In addition, no membrane potential shift was observed when UCP3 expression was not induced ( Figure 8B). Two membrane potential peaks were observed after UCP3 induction ( Figure 8C). Similar results were observed for UCP2 (Fleury et al., 1997, Nature Genetics 15: 269- 272). The most likely explanation for this observation is that one peak represents cells with reduced membrane potential due to expression of UCP3 while the other peak represents cells with normal membrane potential due to the loss of UCP3 expression.
  • UCP3 The expression pattern of UCP3 appears to be unique, because it is abundantly and nearly exclusively expressed in skeletal muscle. Even though UCP3 expression was also detected in the heart and brain, it was found at much lower levels. Skeletal muscle is responsible for more than half of energy expenditure at resting stage. Differences in energy expenditure of skeletal muscle can explain most of the variation in basal metabolic rate between individuals (Ravussin and Bogardus, 1992, Am J Clin Nutr 55: 242S-245S). The proton leak was shown to account for around one-half of the resting respiration rate of perfused rat skeletal muscle (Rolfe and Brand, 1996, Am J Physiol 271: C1380-1389).
  • UCP3 should provide a significant contribution to the uncoupling activities in skeletal muscle since it is much more strongly expressed than UCPl and UCP2, and its activity is likely to be dependent on free fatty acids.
  • the primer pair 3U3F (SEQ ID NO:7) and 3U3R (SEQ ID NO:8) of ucp3 was used to carry out PCR reactions with the 83 clones of the Stanford radiation hybrid panel (Cox et al., 1990, Science, 250:245:250). The PCR results were scored and submitted to the Stanford Genome Center for linkage analysis. It was found that ucp3 is located close to the marker DllS944e with a lod score of 9.4, which corresponds to the cytogenetic location of Ilql3.1 ⁇ llq23.3.
  • UCP2 The chromosomal regions where UCP2 resides are linked to obesity and hyperinsulinemia in both human and mouse, and so UCP2 was hypothesized to be a candidate gene for these diseases (Taylor and Phillips, 1996, Genomics 34, 389-398; Fleury et al., 1997, Nature Genetics 15: 269-272).
  • the close location of UCP3 to UCP2 suggests that UCP3 is also a candidate gene for obesity and hyperinsulinemia.
  • the close homology and location between UCP2 and UCP3 suggested that the two genes arose from a gene duplication event after UCPl was separated.
  • UCP3 Alignment of the six protein sequences of UCPl to UCP3 of human and mouse reveals a highly clustered pattern of the conserved residues.
  • the transmembrane domains and their immediate following sequences are much more conserved than the sequences between the transmembrane domains.
  • each allbnb motif following the first transmembrane domain of each repeat unit is perfectly conserved among the six proteins.
  • UCP3 is a typical member of the mitochondria transport protein superfamily. UCPl activity is inhibited by nucleotides but activated by free fatty acids.
  • UCP2 and UCP3 contain a Tyr instead of a Phe at this position, suggesting that UCP2 and UCP3 has higher basal activity.
  • UCPl and UCP3 both have a Thr at the position corresponding residue 264 of UCPl whereas UCP2 has an Arg.
  • the presence of a positively charged residue in this motif may imply a higher affinity of UCP2 for nucleotides and, consequently, increased sensitivity to nucleotide-mediated inhibition.
  • the very C-terminus of UCPl was shown to be important for activation by fatty acids (Gonzalez-Barroso et al., 1996, Eur J Biochem 239: 445-450).
  • mice All animal experiments were carried out in accordance with our institutional guidance.
  • a total of 10 age-match female ob /ob mice were weighed and injected through tail vein (TV) as follows: three with El- deleted replication deficient adenoviral vector expressing leptin (Ad- leptin), three with helper-dependent adenoviral vector expressing leptin(HD-leptin), two with ⁇ -gal-expressing adenoviral vector(Ad- ⁇ - gal), and two were injected with buffer alone.
  • the animals were then monitored for weight on a daily basis and sacrificed after one week of observation. Blood was collected for each animal and serum leptin levels were determined by Linco Research Inc. (St. Charles, MO) using an RIA assay.
  • leptin treatment leads to increased UCP3 expression in skeletal muscle in ob/ob mice.
  • Leptin plays a pivotal role in the regulation of food intake and energy expenditure.
  • Leptin-deficient ob/ob mice are hyperphagic and hypometabolic, and leptin treatment led to decreased food intake and increased metabolic rate (Halaas et al., 1995, Science 269: 543-546, Hwa et al., 1997, Am J Physiol 272, R1204-1209; Hwa et al., 1996 Horm Metab Res :28: 659-663).
  • Mouse UCP3 was isolated by semi-nested PCR followed by 5' and 3' race.
  • Three degenerate PCR primers were designed based on the conserved regions of the three uncoupling proteins: F441, 5'- CCNCTGGAYACNGCYAA-3' (SEQ ID NO: 19); F755, 5'- CAGCCCACNGANGTNGT-3' (SEQ ID NO:20); and R1055,
  • MOLECULE TYPE cDNA
  • TTTTTTTTGT TCTTACTCCC ACACCTAAGG TGGAANTTCT TTTATTGAGT CATAATAATT 60
  • MOLECULE TYPE other nucleic acid
  • /desc "oligonucleotide"
  • MOLECULE TYPE other nucleic acid
  • /desc "oligonucleotide'
  • CTCCTCTCGG CCCTAAAGGG ACTGGGCAGA GCCTTCCAGG ACTATGGTTG GACTGAAGCC 360 TTCAGACGTG CCTCCCACCA TGGCTGTGAA GTTCCTGGGG GCAGGCACAG CAGCCTGTTT 420
  • CAGCATACAC CTCGGGCCAT CCAGGAGCGA CAGAAAATAC AGCGGGACTA TGGACGCCTA 840
  • GCAAAGGAAC CAGGCCCATT CCCCGGGACC ATGGTTGGAC TTCAGCCCTC CGAAGTGCCT 240

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne une molécule d'acide nucléique isolé codant une nouvelle protéine de découplage d'origine humaine (UCP3), des vecteurs d'expression recombinants s'y rapportant, des cellules hôtes recombinantes, ainsi que des formes globalement purifiées de la protéine UCP3. L'acide nucléique isolé et les protéines décrits dans cette invention sont utiles lors de procédés qui visent à identifier les composés modulant les dépenses d'énergie et la régulation du poids du corps, et qui permettent combattre des maladies telles que l'obésité et le diabètes ainsi que l'hypermétabolisme associé à une mitochondrie. Les acides nucléiques isolés décrits dans la présente invention peuvent en outre être utilisés comme agents potentiels de thérapie génique chez un mammifère hôte, y compris chez les êtres humains.
PCT/US1998/010215 1997-05-20 1998-05-19 Proteine 3 de decouplage d'origine humaine WO1998052958A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP19980923517 EP1012155A4 (fr) 1997-05-20 1998-05-19 Proteine 3 de decouplage d'origine humaine
CA002289945A CA2289945A1 (fr) 1997-05-20 1998-05-19 Proteine 3 de decouplage d'origine humaine
JP55052298A JP2002502240A (ja) 1997-05-20 1998-05-19 ヒト脱共役タンパク質３

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4717997P 1997-05-20 1997-05-20
US60/047,179 1997-05-20
GB9716886.8 1997-08-08
GBGB9716886.8A GB9716886D0 (en) 1997-08-08 1997-08-08 Human uncoupling protein 3
US6914197P 1997-12-09 1997-12-09
US60/069,141 1997-12-09

Publications (1)

Publication Number Publication Date
WO1998052958A1 true WO1998052958A1 (fr) 1998-11-26

Family

ID=27268968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/010215 WO1998052958A1 (fr) 1997-05-20 1998-05-19 Proteine 3 de decouplage d'origine humaine

Country Status (4)

Country Link
EP (1) EP1012155A4 (fr)
JP (1) JP2002502240A (fr)
CA (1) CA2289945A1 (fr)
WO (1) WO1998052958A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620594B1 (en) 1997-05-07 2003-09-16 Novartis Ag Uncoupling protein homologue: UCP 3
US6967245B2 (en) 1998-11-30 2005-11-22 Genentech, Inc. Ucp5
US7342102B2 (en) 1998-11-30 2008-03-11 Genentech, Inc. Uncoupling protein 5 (UCP5)
US8067229B2 (en) 1998-09-22 2011-11-29 Genentech, Inc. Ucp4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2247799A1 (fr) * 1997-03-05 1998-09-11 Smithkline Beecham P.L.C. Polynucleotides et polypeptides appartenant a la famille des proteines non liantes
US6620594B1 (en) * 1997-05-07 2003-09-16 Novartis Ag Uncoupling protein homologue: UCP 3

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GONG D.-W., ET AL.: "UNCOUPLING PROTEIN-3 IS A MEDIATOR OF THERMOGENESIS REGULATED BY THYROID HORMONE, BETA3-ADRENERGIC AGONISTS, AND LEPTIN.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 272., no. 39., 26 September 1997 (1997-09-26), US, pages 24129 - 24132., XP002912749, ISSN: 0021-9258, DOI: 10.1074/jbc.272.39.24129 *
See also references of EP1012155A4 *
SOLANES G., ET AL.: "THE HUMAN UNCOUPLING PROTEIN-3 GENE.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 272., no. 41., 10 October 1997 (1997-10-10), US, pages 25433 - 25436., XP002912748, ISSN: 0021-9258, DOI: 10.1074/jbc.272.41.25433 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620594B1 (en) 1997-05-07 2003-09-16 Novartis Ag Uncoupling protein homologue: UCP 3
US8067229B2 (en) 1998-09-22 2011-11-29 Genentech, Inc. Ucp4
US8313927B2 (en) 1998-09-22 2012-11-20 Genentech, Inc. Ucp4
US8648174B2 (en) 1998-09-22 2014-02-11 Genentech, Inc. Ucp4
US6967245B2 (en) 1998-11-30 2005-11-22 Genentech, Inc. Ucp5
US7342102B2 (en) 1998-11-30 2008-03-11 Genentech, Inc. Uncoupling protein 5 (UCP5)

Also Published As

Publication number Publication date
CA2289945A1 (fr) 1998-11-26
JP2002502240A (ja) 2002-01-22
EP1012155A1 (fr) 2000-06-28
EP1012155A4 (fr) 2002-11-04

Similar Documents

Publication Publication Date Title
WO1999059618A1 (fr) Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)
JP2001228137A (ja) Ｃ３ａ受容体およびＣ３ａを用いるスクリーニング方法
US6245526B1 (en) Lipid metabolism transcription factor
CA2304828A1 (fr) Recepteur hormonal hg38 de glycoproteine couple a la proteine g
EP1045908A2 (fr) Urotensine humaine ii
WO1998052958A1 (fr) Proteine 3 de decouplage d'origine humaine
US7001742B1 (en) Human uncoupling protein 3
US5504192A (en) Human insulin receptor endocytic code binding protein
US6054295A (en) DNA molecules encoding human nuclear receptor proteins
WO2007049065A2 (fr) Proteine contenant des domaines vwfa, collagene et kunitz
EP1973936A1 (fr) Proteine contenant un domaine reeler
US7060463B2 (en) DNA molecules encoding Macaca mulatta androgen receptor
JPH10117788A (ja) ヒト・ｍｙｔ−１キナーゼクローン
EP1084274A1 (fr) Acrp30r2, un homologe d'acrp30 (proteine apparentee au complement de l'adipocyte 30 kd)
EP1007540A1 (fr) Molecules d'adn codant pour des proteines receptrices nucleaires
US6811987B1 (en) Human calcium binding protein and a polynucleotide encoding the same
US20020001823A1 (en) Novel compounds
US20010029031A1 (en) Polynucleotides encoding human sodium bicarbonate cotransporters
EP1185647A1 (fr) Nouveaux composes
US20040091861A1 (en) Novel polypeptide-human shc protein 43 and polynucleotide encoding it
US20030119100A1 (en) DNA molecules encoding human nuclear receptor proteins
CA2315273A1 (fr) Molecules d'adn codant le recepteur proteique nucleaire nnr4 de vertebres
US20040248091A1 (en) Novel polypeptide-human g-protein and the polynucleotide encoding the same
WO1999062947A1 (fr) Gene homologue ci-pdsw de la sous-unite de l'ubiquinone oxyreductase humaine (cblaic08)
WO2008032053A1 (fr) Variantes d'épissure fhr-4a

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998923517

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2289945

Country of ref document: CA

Ref country code: CA

Ref document number: 2289945

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 550522

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998923517

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998923517

Country of ref document: EP